Ketotifen in HIV-infected patients: Effects on body weight and release of TNF-α

European Journal of Clinical Pharmacology

Volumn 50, Issue 3, 1996, Pages 167-170

  Ockenga, J ^a   Rohde, F ^a   Suttmann U ^a   Herbarth, L ^a   Ballmaier, M ^a   Schedel, I ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

HIV infection; Ketotifen; nutritional status; Tumor Necrosis Factor alpha; Tumor Necrosis Factor Receptors

Indexed keywords

KETOTIFEN; KETOTIFEN FUMARATE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NUTRITIONAL STATUS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADULT; BODY WEIGHT; FEMALE; HIV WASTING SYNDROME; HUMANS; KETOTIFEN; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; POKEWEED MITOGENS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0029945502     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050087     Document Type: Article

References (24)

1. Weiss RA (1993) How does HIV cause AIDS? Science 260: 1273-1279
2. Fauci AS (1991) Immunopathogenic mechanisms in human immunodeficiency virus (HIV) Infection. Ann Intern Med 114:678-693
3. Rekka S, Kotler DP (1993) Detection and localisation of HIV RNA and TNF mRNA in rectal biopsies from patients with AIDS. Cytokine 305-308
4. Süttmann U, Selberg O, Gallati H, Ockenga J, Deicher H, Müller MJ (1994) Tumor necrosis factor receptor levels are linked to the acute-phase response and malnutrition in human-immunodeficiency virus-infected patients. Clin Science 86:461-467
5. Zangerle R, Reibnegger G, Wachter H, Fuchs D (1993) Weight loss in HIV-1 infection is associated with immune activation. AIDS 175-181
6. Grunfeld C, Feingold KR (1992) Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. N Engl J Med 329-337
7. Reddy MM, Sorrell SJ, Lange M, Grieco MH (1988) Tumor necrosis factor and HIV p24 antigen in the serum of HIV-infected population. J Acquir Immune Defic Syndr 1:436-440
8. Grunfeld C, Kotler DP, Shigenaga JK, et al (1991) Circulating interferon alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 154-162
9. Gehr G, Braun T, Lesslauer W (1992) Cytokines, receptors, and inhibitors. Clin Investig 70:64-69
10. Aukrust P, Liabakk NB, Müller F, Lien E, Espevik T, Froland SS (1994) Serum levels of tumor necrosis factor-α (TNF-α) and soluble TNF receptors in human immunodefeciency virus type 1 infection correlations to clinical, immunolgic, and virologic parameters. J Infect Dis 169:420-424
11. Schedel I, Ballmaier M, Rohde F, Süttmann U, Deicher H (1994) Ketotifen inhibits tumor necrosis factor α production in the peripheral blood mononuclear cells of patients infected with human immunodeficiency virus. J Interferon Res 14:291-292
12. Rohde F (1995) TNF-α und PGE2 in PBMC-Kurzzeitkulturen HIV-Infizierter-Inhibition der TNF-α Freisetzung durch Ketotifen. Medical Dissertation, Medical School Hannover, Hannover
13. Ballmaier M (1994) Untersuchungen zur TNF-α Produktion und deren Suppressionsmög-lichkeiten bei der HIV-1 Infektion. Biological Dissertation, Medical School Hannover, Hannover
14. Centers for Disease Control (1987) Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR 36:1S-15S
15. Süttmann U, Ockenga J, Selberg O, Hoogestraat L, Deicher H, Müller MJ (1995) Incidence and prognostic value of malnutrition in human immunodeficiency virus-infected outpatients. J Acquir Immune Defic Syndr 8:239-246
16. Peters A, Jäger FS, Warneke A, et al (1991) Cytokine secretion by peripheral blood monocytes from human immunodeficiency virus-infected patients is normal. Clin Immunol Immunopathol 61:343-352
17. Grant SM, Goa KL, Fitton A, Sorkin EM (1990) Ketotifen. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in asthma and allergic disorders. Drugs 40:412-448
18. Maclay WP, Crowder D, Spiro S, Turner P (1984) Postmarketing surveillance: practical experience with ketotifen. Br Med J 288:911-914
19. Rohde F, Ballmaier M, Schedel I, Deicher H (1992) Ketotifen inhibits the production (secretion) of TNF-α in PBMC of HIV-infected individuals. 3rd European Conference on Clinical Aspects and Treatment of HIV Infection, Paris, 1992
20. Dezube BJ, Pardee AB, Chapman B, et al (1993) Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS. NIAD AIDS Clinical Trial Group. J Acquir Immune Defic Syndrom 6:787-794
21. Luke DR, McCreedy BJ, Sarnoski TP, et al (1993) Phase I/II study of pentoxifylline with zidovudine on HIV-1 growth in AIDS patients. Int J Clin Pharmacol Ther Toxicol 31:343-350
22. Karmeli T, Eliakim R, Okon E, et al (1991) Gastric mucosal damage by ethanol is mediated by substance P and prevented by ketotifen, a mast cell stabilizer. Gastroenterology 100:1206-1216
23. Eliakim R, Karmeli T, Okon E, et al (1992) Ketotifen effectively prevents mucosal damage in experimental colitis. Gut 33:1498-1503
24. Ullrich R, Zeitz M, Heise W, et al (1989) Small intestinal structure and function in patients infected with human immunodeficiency virus (HIV): evidence for HIV-induced enteropathy. Ann Intern Med 111:15-20